Local US govts reject $18B opioids settlement - Breaking The News

Local US govts reject $18B opioids settlement

18 October

1 min read

The negotiations with drug distributors hit a wall on Friday at the Northern District of Ohio, lawyer Paul Hanly said on behalf of thousands of local authorities in the United States which sued them and pharmaceutical producers for the opioid crisis. US states were apparently more inclined to settle where the figure was said to have been in the vicinity of $18 billion.

A trial with claims from the counties of Cuyahoga and Summit is now scheduled to begin on October 21. AmerisourceBergen Corp., Cardinal Health Inc., McKesson Corp., Teva Pharmaceutical Industries Ltd., Henry Schein Inc. and Walgreen Boots Alliance Inc were participating in the talks.

The federal case concerns 400,000 deaths officially registered between 1999 and 2017.

pharma teva walgreens mckesson opioid crisis cardinal health henry schein amerisourcebergen

Sycamore to take Walgreens private in up to $24B deal

6 March

Walgreens Boots Alliance has reached a deal worth up to $23.7 billion with private equity group Sycamore Partners that will bring the pharmacy chain's nearly 100-year run as a publicly traded company to an end.Sycamore will pay $11.45 per share in cash for Walgreens. Shareholders could also receive up to $3 more per share in the future from sales of Walgreens' primary-care businesses, including Village Medical, Summit Health and CityMD.Including debt...

Walgreens allegedly closing in on $10B deal to go private

4 March

Walgreens Boots Alliance Inc. is supposedly nearing a deal with private equity firm Sycamore Partners to go private for around $10 billion, the Wall Street Journal reported, citing people familiar with the matter. The two sides are aiming to finish up a deal as soon as Thursday and have been talking about Sycamore paying between $11.30 a share and $11.40 a share in cash, the unnamed sources said. If Sycamore completes the deal for the whole company,...

Roche's 2024 sales up 7% to 60.5B Swiss francs

30 January

F. Hoffmann-La Roche AG said on Thursday its annual sales in 2024 reached 60.5 billion Swiss francs, climbing 3% in Swiss francs and 7% at constant exchange rates (CER) from the same period a year earlier. Sales in the pharmaceuticals division grew 8% at CER to 46.2 billion Swiss francs, while diagnostics division sales rose 4% at CER year on year to 14.3 billion Swiss francs.In the year, net income dropped 19% at CER to 9.2 billion Swiss francs...

Purdue Pharma owners to pay up to $7.4B in opioid settlement

23 January

New York Attorney General Letitia James announced on Thursday that the Sackler family members, who own the OxyContin maker Purdue Pharma, reached a settlement to pay up to $7.4 billion "for their instrumental role in creating the opioid crisis."According to the new settlement, the Purdue Pharma owners will contribute up to $7.4 billion over the span of 15 years, with a portion of the money going to the victims of the opioid crisis. The first payment of $1.5...

This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.